Servier

187 articles with Servier

• Servier full year 2021/22 results confirm the transformation trajectory of the Group

  2/2/2023

  Servier, an independent global pharmaceutical group, has announced its financial results for the 2021/22 financial year and highlighted the major steps of its ongoing transformation.

• Servier and Taiho Oncology Present Overall Survival Data for Trifluridine/Tipiracil (LONSURF®) In Combination With Bevacizumab in Patients With Refractory Metastatic Colorectal Cancer at 2023 ASCO Gastrointestinal Cancers Symposium

  1/17/2023

  Servier and Taiho Oncology, Inc., today announced the release of data from SUNLIGHT, a pivotal Phase 3 global trial evaluating the combination of trifluridine/tipiracil (LONSURF®) and bevacizumab in adults with refractory metastatic colorectal cancer (mCRC), demonstrating that the trial met its primary endpoint of overall survival (OS).

• Real-World Analysis Suggests Pediatric-Inspired Regimens Lead to Higher Overall Survival in Adolescent and Young Adult Patients with Newly-Diagnosed Acute Lymphoblastic Leukemia

  12/12/2022

  Servier announced findings from a retrospective study observing higher overall survival in adolescent and young adult newly-diagnosed acute lymphoblastic leukemia patients treated with asparaginase containing pediatric-inspired regimens versus non-pediatric-inspired regimens.

• Servier Presents Patient Follow Up Data from the Phase 3 AGILE Study at ASH 2022

  12/10/2022

  Servier presented new data at the 64th Annual Meeting of the American Society of Hematology characterizing clonal evolution and relapse mechanisms in patients with newly-diagnosed IDH1-mutated acute myeloid leukemia who are 75 years of age or older or have comorbidities that preclude use of intensive induction chemotherapy treated with TIBSOVO in combination with azacitidine.

• New Data at ASH 2022 Bolster Servier's Leadership in Hematology Research

  11/3/2022

  Servier, a leader in oncology committed to bringing the promise of tomorrow to the patients we serve, will present new data in acute lymphoblastic leukemia and acute myeloid leukemia at the 64th Annual Meeting of the American Society of Hematology taking place December 10–13, 2022.

• 

  Allogene Stocks Fall as Servier Abandons Anti-CD19 Partnership

  9/22/2022

  Allogene Therapeutics' French partner Servier has withdrawn all involvement in the development of Allogene’s anti-CD19 products, allowing Allogene to license its CD19 products outside the U.S.

• Drug Combination Meets Survival Endpoint in Phase III Pivotal Trial Involving Participants With Refractory Metastatic Colorectal Cancer

  9/12/2022

  Servier, Taiho Oncology, Inc., and Taiho Pharmaceutical Co., Ltd., announced today that the investigational combination of trifluridine/tipiracil plus bevacizumab showed a statistically significant improvement in the primary endpoint of overall survival (OS) compared to trifluridine/tipiracil alone in a Phase III clinical trial of participants with refractory metastatic colorectal cancer (mCRC) following two chemotherapy regimens.

• Servier to Showcase Growing Oncology Portfolio at the ASCO and EHA 2022 Annual Meetings

  6/1/2022

  Wide range of research across tumor types underscores Servier's commitment to discovering novel approaches to addressing difficult-to-treat cancers.

• Phase 3 AGILE Data of TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine for Patients with Previously Untreated IDH1-mutated Acute Myeloid Leukemia Published in the New England Journal of Medicine

  4/21/2022

  Global Phase 3 trial of TIBSOVO (ivosidenib tablets) met its primary endpoint of event-free survival and all key secondary endpoints, complete remission rate, overall survival, complete remission and complete remission with partial hematologic recovery rate.

• Servier Announces FDA Filing Acceptance and Priority Review for TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine for Patients with Previously Untreated IDH1-mutated Acute Myeloid Leukemia

  3/7/2022

  Servier today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental New Drug Application (sNDA) for TIBSOVO.

• Phase 3 Data Demonstrate TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine Significantly Improves Event-Free Survival and Overall Survival in Patients with Previously Untreated IDH1-mutated Acute Myeloid Leukemia

  12/11/2021

  Servier announced Phase 3 data demonstrating that TIBSOVO® in combination with the chemotherapy azacitidine significantly improved event-free survival and overall survival compared to azacitidine plus placebo in adults with previously untreated IDH1-mutated acute myeloid leukemia who are not candidates for intensive chemotherapy.

• New Data at ASH 2021 Reinforces the Strength of Servier's Hematology Portfolio

  11/4/2021

  Servier, a growing leader in oncology committed to bringing the promise of tomorrow to the patients we serve, announced new data in acute myeloid leukemia to be presented at the 63rd Annual Meeting of the American Society of Hematology taking place December 11 – 14, 2021.

• Servier Announces Positive Topline Data from the Global Phase 3 Study of TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine in Patients with Previously Untreated IDH1-mutated Acute Myeloid Leukemia

  8/2/2021

  Servier, a global pharmaceutical company, announced the global Phase 3 double blinded placebo controlled AGILE study of TIBSOVO in combination with the chemotherapy azacitidine in adults with previously untreated IDH1-mutated acute myeloid leukemia met its primary endpoint of event-free survival.

• Servier Announces Promising Phase 1 Data for Vorasidenib in IDH Mutant Low-Grade Glioma Published in Clinical Cancer Research

  6/16/2021

  - Servier today announced that Clinical Cancer Research has published data from its Phase 1 study evaluating single-agent vorasidenib in isocitrate dehydrogenase (IDH) mutant advanced solid tumors, including low-grade glioma.

• Servier Presents Updated Translational Data from Perioperative Study of Vorasidenib and TIBSOVO® (ivosidenib tablets) in Patients with IDH Mutant Low-Grade Glioma at ASCO 2021

  6/7/2021

  Data suggest short-term treatment with vorasidenib and TIBSOVO reduces tumor cell proliferation, alters epigenetic state, and promotes expression of genes associated with cellular differentiation BOSTON , J

• Servier Completes Acquisition of Agios Pharmaceuticals' Oncology Business

  4/1/2021

  Transaction includes TIBSOVO®, co-commercialization responsibilities for Bristol Myers Squibb's IDHIFA® as well as a strong oncology pipeline of Phase 3 and early-stage assets

• Agios Announces Closing of Oncology Business Sale to Servier

  4/1/2021

  Agios Receives $1.8 Billion in Upfront Cash to Focus on Accelerating and Expanding its Genetically Defined Disease Portfolio Agios Enters Into Agreement to Repurchase Approximately 10% of Its Outstanding Shares from Bristol-Myers Squibb for $344.5 Million

• Servier and MiNA Therapeutics Enter Collaboration in Neurological Diseases

  1/21/2021

  MiNA eligible for up to 220 M€ in upfront, development and commercial milestone payments for first target.

• Taiho Oncology and Servier To Present Data on LONSURF® (trifluridine and tipiracil) at 2021 ASCO Gastrointestinal Cancers Symposium (ASCO GI)

  1/12/2021

  Taiho Oncology, Inc. and Servier today announced that data for LONSURF ® (trifluridine and tipiracil) in previously treated patients with metastatic gastric cancer (mGC) and metastatic gastroesophageal junction adenocarcinoma (mGEJC) will be presented during the 2021 American Society of Clinical Oncology Gastrointestinal Cancers

• Servier to Acquire Agios Pharmaceuticals' Oncology Business

  12/21/2020

  - Transaction includes commercial, clinical and research-stage oncology portfolio and employees for up to $2 Billion plus royalties - Includes Agios' marketed medicine TIBSOVO® and a strong oncology pipeline of Phase 3 and early-stage assets - Acquisition in-line with Servier's strategic ambition to become a recognized and innovative player in oncology, supported by unique drug discovery capabilities